Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Twist Bioscience's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Twist Bioscience's regulatory disclosures and financial reporting.
Twist Bioscience Corp executive Paula Green, SVP of Human Resources, reported a small mandated share sale tied to equity compensation. On June 22, 2026, she sold 291 shares of common stock at $87.3224 per share solely to cover tax withholding on vesting Restricted Stock Units. After this tax-related transaction, she directly held 120,414 shares of Twist Bioscience common stock.
Twist Bioscience Corp executive Dennis Cho reported a mandated sale of 346 shares of Common Stock. The shares were sold at an average price of $87.3224 per share to cover tax withholding obligations arising from the vesting of Restricted Stock Units under the company’s equity incentive plans.
According to the filing footnote, this was a required "sell to cover" transaction and not a discretionary trade by Cho. Following this tax-related sale, he directly owned 119,346 shares of Twist Bioscience Common Stock.
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported an open-market sale of 1,688 shares of common stock at $87.3224 per share. According to the disclosure, this sale was required to cover tax withholding obligations tied to vesting Restricted Stock Units under the company’s equity incentive plans and was not a discretionary trade.
After this transaction, Leproust directly holds 842,919 shares of Twist Bioscience common stock. She also retains employee stock options covering 64,950 underlying shares at an exercise price of $67.85 per share that are outstanding and expire on August 31, 2030.
Twist Bioscience-related reporting person reported sales of Common Stock in multiple transactions. The largest single sale listed was 14,205 shares for $990,798.75 on 05/29/2026, with additional sales of 1,962 shares ($112,125.95), 1,642 shares ($87,447.34), 402 shares ($28,077.37), and 346 shares ($30,213.55) on the dates shown.
Emily M. Leproust reported multiple sales of Common stock. The filings list open‑market dispositions on several dates between 04/21/2026 and 06/08/2026 with individual trades such as 24,282 shares on 05/26/2026 for $1,580,245.85 and 25,017 shares on 05/27/2026 for $1,633,407.46. The excerpt also records a restricted stock vesting of 1,688 shares on 06/18/2026.
Issuer reported insider sales and a restricted-stock vesting. The filing lists a Restricted Stock Vesting of 346 shares on 06/18/2026 recorded as compensation. It also discloses multiple sales by Dennis H. Cho: 1,962 shares on 05/04/2026, 1,642 shares on 05/21/2026, 14,205 shares on 05/29/2026, and 402 shares on 06/08/2026, with proceeds shown in the filing for each sale.
Form 144 notice: proposed sale of Common Stock related to TWST. The filing lists a proposed sale of 291 shares tied to restricted stock vesting on 06/18/2026 described as Compensation. The filing also reports multiple sales by Paula Green during the past three months: 1,116 shares on 05/04/2026, 1,399 shares on 05/21/2026, 884 shares on 06/08/2026, and 26,137 shares on 06/15/2026, each with the dollar amounts shown in the excerpt.
Twist Bioscience filed a shelf registration and a sales agreement to offer up to $200,000,000 of its common stock for issuance from time to time under an at-the-market program. The company may sell shares through TD Securities (USA) LLC ("TD Cowen") as sales agent or principal.
The prospectus clarifies that sales will be at market prices and the timing, amounts and prices will vary by placement notices. Proceeds from shares sold under the Sales Agreement will be used for general corporate purposes, including working capital, with management retaining broad discretion. The prospectus incorporates Twist’s SEC reports, shows 62,154,412 shares outstanding as of March 31, 2026, and provides illustrative figures using a last reported price of $84.95 per share.
Twist Bioscience Corp SVP of Human Resources Paula Green reported option exercises and share sales. On June 15, 2026, she exercised employee stock options for 26,137 shares of common stock at an exercise price of $23.33 per share. The same day, she made open‑market sales of 24,109 shares at a weighted average price of $81.6233 and 2,028 shares at a weighted average price of $82.1655. After these transactions, she directly owned 120,705 shares of Twist Bioscience common stock.
TWST proposes sale of 26,137 shares of Common Stock via stock option exercise. The filing states the sale date as 06/15/2026 and lists Fidelity Brokerage Services LLC as the broker-dealer. The filing also lists recent dispositions by Paula Green totaling 3,696 shares on 03/20/2026, 05/04/2026, 05/21/2026, and 06/08/2026 with cash amounts shown for each sale.